

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau


(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/127088 A1

- (51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
- (21) International Application Number:
PCT/US2020/065474
- (22) International Filing Date:
17 December 2020 (17.12.2020)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/949,499 18 December 2019 (18.12.2019) US
62/949,492 18 December 2019 (18.12.2019) US
62/949,507 18 December 2019 (18.12.2019) US
62/949,486 18 December 2019 (18.12.2019) US
62/949,502 18 December 2019 (18.12.2019) US
62/949,513 18 December 2019 (18.12.2019) US
62/949,519 18 December 2019 (18.12.2019) US
62/949,526 18 December 2019 (18.12.2019) US
63/091,100 13 October 2020 (13.10.2020) US
- (71) Applicant: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, PA 19044 (US).
- (72) Inventors: GANESAN, Rajkumar; 1400 Mckean Road,
Spring House, PA 19477 (US). SINGH, Sanjaya; 1400
Mckean Road, Spring House, PA 19477 (US). GREW-
AL, Iqbal, S.; 1400 Mckean Road, Spring House, PA
19477 (US). HANSEN, Michael, Riis; 1400 Mckean Road,
Spring House, PA 19477 (US).
- (74) Agent: WEISSER, Tamera, M. et al.; Jones Day, 250
Vesey Street, New York, NY 10281-1047 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: MATERIALS AND METHODS FOR IN VIVO BIOLOGICAL TARGETING



(57) Abstract: An isolated molecule, comprising: a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain specifically binds CD8 and the second antigen binding domain specifically binds a T cell receptor (TCR) complex. In another aspect, the disclosure provides an isolated molecule, comprising: a first antigen binding domain, a second antigen binding domain and a third antigen binding domain, wherein the first antigen binding domain specifically binds CDS, the second antigen binding domain specifically binds a TCR complex, and the third antigen binding domain binds a third antigen.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))